We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
In an interview on CNBC, a Jefferies analyst said that Biogen ( BIIB-29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company ( BHVN+8.2%), Neurocrine Biosciences ( NBIX+5.9%), Alder BioPharmaceuticals ( ALDR+6.2%), Sage Therapeutics ( SAGE+3.6%), ACADIA Pharmaceuticals ( ACAD+3.7%) and GW Pharmaceuticals ( GWPH+3.3%).
A Stifel analyst agreed, adding that Sarepta Therapeutics ( SRPT+2.1%) could be a target as well.